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Background: At an early stage, prostate cancer patients are often eligible for more than one treatment option, or
may choose to defer curative treatment. Without a pre-existing superior option, a patient has to weigh his personal
preferences against the risks and benefits of each alternative to select the most appropriate treatment. Given this
context, in prostate cancer treatment decision-making, it is particularly suitable to follow the principles of shared
decision-making (SDM), especially with the support of specific instruments like decision aids (DAs). Although several
alternatives are available, present tools are not sufficiently compatible with routine clinical practice. To overcome
existing barriers and to stimulate structural implementation of DAs and SDM in clinical practice, a web-based
prostate cancer treatment DA was developed to fit clinical workflow. Following the structure of an existing DA,
Dutch content was developed, and values clarification methods (VCMs) were added. The aim of this study is to investigate
the effect of this DA on (shared) treatment choice and patient-reported outcomes.
Methods/design: Nineteen Dutch hospitals are included in a pragmatic, cluster randomized controlled trial, with an
intervention and a control arm. In the intervention group, the DA will be offered after diagnosis, and a summary of the
patients’ preferences, which were identified with the DA, can be discussed by the patient and his clinician during later
consultation. Patients in the control group will receive information and decisional support as usual. Results from both
groups on decisional conflict, treatment choice and the experience with involvement in the decision-making process are
compared. Patients are requested to fill in questionnaires after treatment decision-making but before treatment is started,
and 6 and 12 months later. This will allow the development of treatment satisfaction, decisional regret, and quality of life
to be monitored. Clinicians from both groups will evaluate their practice of information provision and decisional support.
Discussion: This study will describe a web-based prostate cancer treatment DA with VCMs. The effect of this DA on the
decision-making process and subsequent patient reported outcomes will be evaluated.
Trial registration: The Netherlands National Trial Register: NTR4554, registration date 1 May 2014.
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Prostate cancer (PrCa) is the most common malignancy
in men in the western world, and in The Netherlands
where more than 10,000 new prostate cancer patients
are diagnosed each year [1]. Incidence is still growing
due to earlier detection and an ageing population [2–4].
Based on demographic developments only, the incidence
of prostate cancer in The Netherlands is expected to in-
crease by 49 % between 2011 and 2030 [5].
For the treatment of localized (low and intermediate
risk) prostate cancer, the most common curative treatment
options include radical prostatectomy, external beam radio-
therapy (EBRT), and brachytherapy. Each curative treat-
ment option has a specific risk profile concerning the
occurrence of treatment side effects (for example, im-
potence, incontinence, and bowel problems). Because
curative treatment may not always be necessary as ini-
tial treatment for low-risk PrCa, active surveillance can
be considered a valid option for avoiding or deferring
the need for curative treatment. Active surveillance has
some known psychosocial barriers like anxiety and un-
certainty about disease progression, which can withhold
patients from choosing this option, although active sur-
veillance is increasingly applied in clinical practice [6, 7].
Clinical practice guidelines do not provide strong treat-
ment recommendations given a lack of convincing evi-
dence indicating superiority of any of the available options
[8]. Choosing the most suitable treatment option therefore
requires a patient to evaluate the treatment procedure,
risk for side-effects and the chance of success for all avail-
able options. Combined with personal preferences and
characteristics, identifying the best suitable treatment op-
tion is a difficult and stressful exercise for many patients
[9, 10]. Further complicating factors are clinicians’ mis-
interpretation of patients’ preferences, (information) needs
and the patient’s preferred role in the decision-making
process [11–15]. Eventually, this may result in the clinician
dominating in the treatment decision-making at the expense
of the patients’ preferences. It is possible that expressing a
dominant clinician view may contribute to observed regional
variations in the management of prostate cancer [16–20].
During the past decade, several decision aids (DAs)
have been developed with a special focus on prostate
cancer care. Instruments range from information booklets
to tailored web-based tools. The variety in the formats
used may have contributed to the finding that effects on
decisional outcomes have been inconsistent across ran-
domized trials and that no effects on choice have been
found [21, 22]. Systematic reviews further emphasize that
many previous studies are at high risk of selection bias
due to inadequate concealment or blinding of data collec-
tors and outcomes assessors, and that more studies are
needed to determine how DAs can be implemented best
in clinical practice [21, 22].Determining the effect of a DA intervention and find-
ing optimal implementation methods are both aims of
the current trial. A web-based prostate cancer treatment
DA was developed to fit with Dutch clinical workflow.
Based on the structure of an existing DA developed by
Feldman-Stewart and colleagues [23, 24], Dutch content
was written and values clarification methods (VCMs) were
added. Adaptation of the DA was based on the Inter-
national Patient Decision Aid Standards (IPDAS) [25].
Methods/design
Objectives and hypothesis
The main objective of this study is to investigate the im-
pact of the DA on shared decision-making and treatment
choice. It is hypothesized that DA usage will improve
prostate cancer knowledge and satisfaction with informa-
tion provision and therefore better prepare patients for
clinical encounters and the following decision-making,
which will result in lower levels of decisional conflict com-
pared to standard care. Further, it is expected that better
knowledge and less decisional conflict will also result in
improved treatment satisfaction, less regret and, ultim-
ately, improved health-related quality of life (HRQoL). In
terms of actual choice, we expect less variation in selected
treatments in the intervention group compared to the
control group.
A secondary aim is to investigate optimal implementa-
tion, as previous studies have emphasized the need to gain
more insight on this matter [21]. From the patient perspec-
tive, it is expected that some subgroups will experience
more benefit from DA usage than others. To identify these
groups, the moderating role of age, preferred role in the
decision-making process, specific health skills (for example,
health numeracy and literacy) and personality on the main
outcomes will be investigated. Healthcare providers in the
intervention group will be asked their opinion about imple-
mentation of the DA. This will be compared with an evalu-
ation of information provision and decisional support as
provided by healthcare providers in the control group.
Study design
The design for this study is a two-armed pragmatic,
cluster randomized controlled trial (CRCT). Clustering
is performed at the hospital level, meaning that all in-
cluded patients from a participating hospital are in the
same study group. Participating hospitals can therefore
provide the same type of care to all of their patients,
making a CRCT less prone to contamination bias [26].
The study will be longitudinal, including patients imme-
diately after prostate cancer diagnosis and following
them for 12 months. Patient-reported outcomes from
both arms will be compared. Involved healthcare profes-
sionals will be included in a survey-study to evaluate
their opinion on working with the DA. A comparison
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control group.
The description of this design follows the CONSORT
recommendation for reporting on trials (www.consort-
statement.org) with the extensions for pragmatic [27]
and cluster [28] randomized trials.
Randomization
Nineteen Dutch hospitals have been randomized to ei-
ther ‘usual care’ (arm 1) or ‘usual care + DA’ (arm 2).
With this so-called prerandomization, the conventional
sequence of obtaining informed consent followed by
randomization is reversed [29]. This prerandomization is
needed because we make clinicians aware (when intro-
ducing the DA) of the principles of shared decision-
making and the characteristics of the DA. This could
affect the control group if they were recruited within the
same hospital.
To prevent potential imbalance between the two arms
that could arise from hospital characteristics (for ex-
ample, hospital size and treatment profile), two strata
were included in the randomization procedure. First, if
cooperation between two hospital locations leads to
overlap in medical staff or patients visiting both loca-
tions, there is a risk for contamination bias if these
hospital locations are not in the same cluster. In our
sample, four pairs of hospitals have this overlap in
hospital staff or patient visits. To maintain variability
in hospital characteristics within each cluster, only two
pairs were allowed to enter the same cluster. The sec-
ond criterion is related to hospital specific treatment
variation. In The Netherlands, hospitals that perform
robot-assisted radical prostatectomy indicate a signifi-
cant larger proportion of their patients for surgery
compared to other hospitals [4]. At the moment of
randomization, three hospitals from our sample are
known for having robotic surgery facilities to treat
prostate cancer patients, and only two of these hospi-
tals were allowed to join the same cluster.
Randomization was performed by a statistician not in-
volved in the study and blind to the identity of the hos-
pitals, using SPSS version 19.0 (Statistical Package for
Social Sciences, Chicago, IL, USA). As a first step, the
four paired hospitals were randomized (block size = 2).
Next, the remaining 11 hospitals were also block ran-
domized (block size = 6, with the last position unused).
A set seed was chosen that fulfilled to the criteria that
only two robot facilitated hospitals were allowed into the
same cluster. The generated group order was then ap-
plied to a pre-existing list of participating hospitals,
which was sorted in alphabetical order. As there is an
uneven number of hospitals participating in this study,
the largest cluster that was formed was identified as the
intervention cluster.Study population, inclusion criteria and exclusion criteria
The DA is developed for the initial treatment decision in
early-stage prostate cancer. In order to be eligible to par-
ticipate in this study, a subject must meet the following
inclusion criteria:
1. Patient is diagnosed with low or intermediate risk
prostate cancer (EAU/ESTRO criteria) [30].
2. Patient is eligible for at least two of following
treatment options: active surveillance, radical
prostatectomy, brachytherapy, external beam
radiotherapy.
3. Patient has access to a PC, laptop or tablet with an
internet connection.
Exclusion criteria are:
1. A combination of PSA ≥10 and Gleason = 7 (which
defines high-risk prostate cancer).
2. Cognitive impairment or being too ill at time of the
study.
3. Insufficient understanding of the Dutch language to
complete questionnaires and understand the DA.
Intervention
After being diagnosed with prostate cancer, but before a
treatment decision has been made, patients in the inter-
vention arm receive access to the online DA. Healthcare
providers are instructed to introduce the DA and the
study at diagnosis. However, the pragmatic nature of this
trial allows hospitals to integrate the introduction of the
DA with their standard information provision routines if
that follows later due to follow-up diagnostics or an add-
itional consultation with (oncology) nurses. In daily prac-
tice, this means that either the urologist or the (oncology)
nurse introduces the DA to the patient. To use the DA,
patients receive a card from their urologist stating their
relevant disease characteristics (PSA, Gleason, and eligible
treatment options) and a personal username and password
to gain online access to the DA. If a nurse introduces the
DA and accompanying access card, the urologist should
provide the requested clinical characteristics to the nurse,
either by filling in the card or by leaving a note in the pa-
tients’ record.
The DA offers a stepwise guidance through the deci-
sion process. In the first step, general information about
prostate cancer is provided. The second step offers the
consideration between active surveillance and curative
treatment (surgery or radiotherapy). Values clarification
statements are presented in this step to elicit a patient’s
preference based on three main differences between AS
and curative treatment; acceptance of deferring treat-
ment (‘I am confident enough that I will be treated on
time, if necessary’ versus ‘I do not want to postpone
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possibly unnecessary treatment (‘If treatment might be un-
necessary, I would rather wait’ versus ‘I prefer treatment,
even if it might be unnecessary’) and the acceptance of
treatment side effects (‘I find possible treatment side effects
like erectile and urinary dysfunctions difficult to accept’
versus ‘I find the possible treatment side effects accept-
able’). Each statement is related to one of the two offered
treatment alternatives in this step. On a slider scale, pa-
tients can indicate for each set of statements the strength
of their preference towards one of the alternatives.
Following the same structure, the next step supports
the consideration between surgery and radiotherapy. For
surgery, three common methods are discussed (laparo-
scopic, open and robot assisted). For radiotherapy this
consists of brachytherapy and EBRT. Again, information
provision is followed by values clarification statements.
The VCMs in this step emphasize the main differences
between surgery and radiation therapy (both brachy and
EBRT) in terms of treatment procedure (‘I find it im-
portant that all cancer cells are removed from my body’
versus ‘I find it important that the cancer cells die and
not grow further’), side effects (‘I find bowel problems
worse than incontinence’ versus ‘I find incontinence
worse than bowel problems’), secondary treatment (‘I am
comforted by the thought that I can have radiation if sur-
gery is unsuccessful’ versus ‘I accept that surgery is diffi-
cult after radiation’) and fear for surgery (‘I am not
anxious about surgery’ versus ‘I am anxious about sur-
gery’). If a patient already indicated a preference for ac-
tive surveillance in the previous step, the program allows
patients to ignore this part and continue to the last step.
As a conclusion, the final step asks patients to indicate
their final treatment preference and briefly explain their
choice. The DA does not provide treatment advice, but
helps the patient to reach an informed preference. A sum-
mary then provides an overview of all answers to the
statements and the patients’ final preference. To discuss
this summary with their urologist, the summary can be
printed or accessed online during the next consultation.
All statements used in the VCMs were developed by a
team of urologists, psychologists and engineers based on
previous experience and observation of conversations
where treatment decisions were discussed. The state-
ments were evaluated during usability-testing among pa-
tients, urologists and nurses (N = 10).
Recruitment
Patients in both arms will be recruited by their treating
urologist. When meeting the inclusion criteria, the urolo-
gist will use a letter and a leaflet, in which the study is
clarified, to invite eligible patients to participate. The letter
and accompanying leaflet about the study will state that
we would like to investigate the information provision anddecision-making process in general, without explicitly
mentioning that a DA is the subject of this study. This re-
duces potential bias from emphasizing that the DA is an
addition to usual care, as the perception of any addition to
usual care may evoke improved satisfaction on itself. It
will also avoid a situation where patients in the control
group feel that they are withheld from a potential helpful
tool. Patients are not informed about the randomization
at the hospital level.
For all logistics involved to distributing and processing
the questionnaires, the PROFILES-application will be
used. ‘Patient Reported Outcomes Following Initial treat-
ment and Long term Evaluation of Survivorship (PRO-
FILES)’ is a registry for the study of the physical and
psychosocial impact of cancer and its treatment from a
dynamic, growing population-based cohort of both short
and long-term cancer survivors. PROFILES was devel-
oped in 2009 by a joint research group from Tilburg
University and Comprehensive Cancer Centre South
(CCCS) with a grant from the Netherlands Organization
for Scientific Research (NWO) [31]. PROFILES enables
data collection management, from inviting patients to
participate in studies to collecting patient-reported out-
comes data via web-based or mailed questionnaires, and
provides a supporting helpdesk. Patients can send their
informed consent form, which they receive with the in-
formation letter to PROFILES. On the informed consent
form patients can indicate whether they want to receive
questionnaires via email or regular mail. Approximately
1 to 2 weeks after treatment decision-making (T1) pa-
tients receive either the invitation (email) to fill in an
online questionnaire or a paper version at their home
address. In the case of a paper version, a stamped self-
addressed envelope is provided to the patient to return
the questionnaire. If patients do not fill in their ques-
tionnaires within two weeks, a reminder letter or email
will be send. Patients will be assured that nonparticipa-
tion does not result in differential follow-up care or
treatment. The PROFILES-application allows for man-
aging the follow-up questionnaires, which are sent at 6
and 12 months following T1.
Outcome measures
Table 1 shows an overview of all outcome measures and
the moment of measurement.
Primary outcomes
Primary outcome is decisional conflict. The decisional
conflict scale (DCS) [32, 33] evaluates the level of deci-
sional conflict on five subscales; the feeling of being
well-informed; the clarity of values; the feeling of sup-
port during the decision-making process; the feeling of
uncertainty about best choice; and the effectiveness of
the decision. The level of decisional conflict is measured
Table 1 Outcome measures
Outcomes Instrument T1 T2 T3
Shared decision-making outcomes
Decisional conflict Decisional Conflict Scale X
Decisional regret Decisional Regret Scale X X
PrCa Knowledge PrCa decision quality instrument X
Satisfaction with information SCIP-B X
Decision-making preparedness Preparation for DM-scale X
Decision-making role PSDM-scale X
Perceived doctor-patient relationship Single item X X X
Actual treatment choice and health outcomes
Initial preference and treatment choice Single items X
Treatment satisfaction Single item X X
Health-related Quality of Life EORTC QLQ-C30 X X X
EORTC QLQ-PR25 X X X
Side-effect impact IIQ-7 subset for emotional state X X
Acceptance & Control over health status Subjective experienced health (SBG) X X X
Cuypers et al. Trials  (2015) 16:231 Page 5 of 10at T1. The DSC is widely accepted and applied as main
outcome measure in (PrCa) DA trials [24, 34–36].
Secondary outcomes
Secondary outcome measures can be categorized as either
shared decision-making outcomes or health outcomes.
Shared decision-making outcomes consist of decisional re-
gret [37], perceived and preferred decision-making role
[38], and preparation for decision-making to assess a pa-
tient’s preparation for decision-making and dialoguing
with his clinician [39]. Furthermore, a single-item ques-
tion will evaluate the perceived patient-doctor relationship
and the development of this relationship over time. Also,
satisfaction with information provision [40] and know-
ledge [41] will be assessed.
Health outcomes refer to the actual treatment choice
and any changes in treatment preference during the
decision-making process. Treatment satisfaction will be
measured with a single-item question: ‘Are you satisfied
with the way your treatment was or is executed?’ To as-
sess health-related quality of life (HRQoL) the EORTC
QLQ-C30 [42] will be used. This questionnaire is devel-
oped specific to assess HRQoL in cancer patients. Much
of the content of the questionnaire is appropriate for
extended monitoring of health status, including scales
assessing physical, role, cognitive and emotional func-
tioning, fatigue and sleep problems, and overall health
and quality of life. This core instrument is supplemented
with the prostate cancer-specific HRQoL questionnaire
EORTC QLQ-PR25 [43]. This 25-item questionnaire as-
sesses urinary, bowel and sexual symptoms and function-
ing, and the side-effects of hormonal treatment, though
hormonal treatment is not offered as initial treatment inthis study’s sample. Health outcomes are further assessed
by means of an evaluation of side-effect impact [44, 45]
and health status acceptance and subjective control [46].
Other measures
Table 2 shows an overview of the other measures. Deci-
sion aid users are asked to evaluate the DA by indicat-
ing for 25 statements if it applies to the responder or
not. The first 11 statements are formulated negatively
(for example, ‘I found the decision aid too difficult’),
followed by 14 positively formulated statements (for ex-
ample, ‘I found the decision aid pleasant to use’). Al-
though literature reports positive effects from the usage
of DAs in general [47], there may be subgroups that
will not benefit from DA-usage. To identify these sub-
groups, additional measures on (health) skills and per-
sonality are included. Objective measures for health
literacy and health numeracy are used, with the HRS
Experimental numeracy module [48] and the STOHFLA-
brief [49], respectively. The Decision Self-Efficacy Scale is
used as a subjective measure of the perceived ability to
make a decision [50].
Comparable to health skills, the relation of personality
to beneficial DA-usage will be investigated. Some studies
suggest a link between personality and treatment choice
[51, 52]. Following these studies, some relevant aspects
of personality will be taken into account: hospital anxiety
and depression (HADS-scale) [53], prostate specific anx-
iety (MAX-PC) [54, 55], optimism (Life Orientation Test -
Revised) [56], the big five personality dimensions (Big Five
Inventory-10) [57], information seeking preferences (sub-
scale from the Autonomy preference index) [58] and
maximization tendencies (Maximization scale) [59].
Table 2 Other measures




Self-efficacy Decision self-efficacy scale X
Health numeracy HRS Experimental numeracy module X
Health literacy STOHFLA-brief X
Psychosocial variables
Anxiety and depression HADS, PC-max X X X
Personality LOT-R, BFI-10 X
Information seeking preferences API, NFC-short, Maximization scale X
Sociodemographics and other healthcare utilization X X X
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utilization
Standard sociodemographics will be asked on age, mari-
tal status, occupation, and education. Also, patients will
be asked to report any additional healthcare utilization
(general practitioner or other medical specialist) in the
past 12 months to assess whether this affects the decision-
making process.
Healthcare providers’ evaluation
Healthcare providers in the intervention arm will be
asked their opinion about implementation of the DA in
qualitative interviews as well as questionnaires at the
end of patient inclusion (approximately after 12 months).
This questionnaire will be based on the MIDI-instrument
[60], which is developed for the evaluation of implement-
ing an innovation in a healthcare setting. The question-
naire will focus on usage of the DA (for example, ‘Did you
offer the DA to all eligible patients?’) and evaluate the pros
and cons of the DA with help of statements (for example,
‘The DA is practical in use’). Healthcare providers in the
control condition will be asked to evaluate the current infor-
mation provision and decision-making processes, their ex-
pectation of DA-usage and motivation for implementation.
Sample size calculation
The sample size for this study is determined by power
analysis with decisional conflict as the primary measure.
To be able to detect a clinically relevant minimum effect
size [61] of .50, power is set at .80 and alpha at .05. With
19 hospitals (clusters) that agreed to participate, it is
needed to estimate the intra-class coefficient (ICC). The
ICC assesses the proportion of variance explained by
clusters. Higher ICC values decrease effective sample
size and statistical power. ICC ranges from 0 to .1 are
considered common in medical literature [62]. A more
specific review of ICC values in (cluster) RCTs with psy-
chosocial measures is provided by Bell and McKenzie[63], which also included a cluster RCT evaluating a
group support tool for prostate cancer patients [64]. The
median estimated value for 82 longitudinal ICCs from
15 included studies was 0.0007, and the range found for
decisional conflict was between 0 and 0.02. Given the
considerable variability in ICCs that is found in litera-
ture, ICC for the current trial is set conservative at 0.01.
The attrition rate is set at 25 % to compensate for
non-response to the questionnaires. This rate is compar-
able to studies in similar populations and following the
same methods as this study does [65, 66]. Calculations
show that a design with 19 clusters of 20 patients (380
patients in total) achieves a power of .8. Taking into ac-
count a 25 % attrition rate between the first and third
questionnaire, the total sample size (rounded) will be set
at 475 patients. This results in a recruitment of 25
patients per hospital.
Statistical analysis
All analyses will be conducted using SPSS version 19.0
(Statistical Package for Social Sciences, Chicago, IL,
USA). A 0.05-significance level will be adopted in all
statistical tests.
We will perform a descriptive statistical analysis of
organizational (hospitals) and socio-demographic (pa-
tients) characteristics in order to assure the compar-
ability of the intervention and control groups. Baseline
measures and changes in outcome variables over the
study period for each study arm will be presented as
means (± SD).
The main outcome decisional conflict is measured at
T1 and will be compared between both groups (inter-
vention and control). Multilevel modelling will be car-
ried to take the hierarchical structure of the data into
account by specifying random effects at both hospital
and patient level. The least square mean proportions will
be estimated and compared to assess the effect of the
DA on decisional conflict.
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both groups using multilevel modelling. Some of the sec-
ondary measures consist of repeated measures (for ex-
ample, HRQoL and decisional regret) and will be treated
according the appropriate mixed-model approach; that is,
repeated measures anova/ancova will be used for out-
comes with two time points (decisional regret, treatment
satisfaction), and a random coefficient approach will be
used for outcomes with three time points (HRQoL) [67].
Observed variation in treatment choice during the trial
period will be compared between groups and at level of
the individual hospital. For this second comparison, each
hospital’s particular historical treatment variation profile
(2008 to 2012) will be obtained from the Netherlands
Cancer Registry.
Potentially confounding variables (for example, per-
sonality, health skills, and age) will be explored for their
impact on the primary and secondary outcomes. Missing
data and drop-outs will be described.
Ethical considerations
The research protocol was examined by the accredited
regional Medical Research Ethics Committee ‘METC
Brabant’, and concluded that participants are not sub-
jected to any procedure or imposed to perform any be-
havior. With this conclusion the obligation to fulfill the
specific requirements of the Dutch law for Medical Re-
search involving Human Subjects (WMO) was waived
(reference: NW2014-03). The science committee of the
initiating hospital has approved the study protocol (ref-
erence: WB/mt/14.030). All participating patients will
sign an informed consent form.
Discussion
This study investigates the effect of an interactive, web-
based, treatment decision aid for early-stage prostate can-
cer. It compares impact on the decision-making process
and patient-reported outcomes from an intervention
group with a control group. Included patients will be
followed for 12 months to investigate long-term conse-
quences from the intervention on regret, treatment satis-
faction and quality of life. Randomization will take place
at the hospital level, meaning that once included, all pa-
tients within in one hospital receive the same treatment.
Compared to randomization on the level of the patient,
this design is less prone to contamination bias. The
strength of this study is the initial involvement of 19 par-
ticipating hospitals. With this large number, a proper vari-
ation of local circumstances can be taken into account
that might affect structural adaptation of the DA in clin-
ical practice. The large number of participating hospitals
also requires careful management by the researchers dur-
ing the trial period. Motivating all involved doctors, nurses
and assistants requires careful monitoring of inclusionprogress per location and adaptation to specific circum-
stances. Another challenge is to take the treatment vari-
ation per hospital into account. If past-year treatment
characteristics appear to be imbalanced between both
arms, we may decide to adjust for past year treatment,
based on hospital-specific treatment profiles obtained
from the Netherlands Cancer Registry.
Although we are aware of the fact that individual differ-
ences between clinicians could also affect decision out-
comes, there are some considerations that justify taking
the institution as the unit of analysis. First, diagnosis and
offered treatment plans are often the result of multi-
disciplinary consideration (for example, urologists, radio-
therapists, and oncologists). Secondly, specialization often
leads to some clinicians seeing the majority of PrCa pa-
tients within an institution. Taking the clinician as unit of
analysis could lead to too small clusters in some cases. On
the other hand, clinician specialization could also lead to
patients visiting multiple clinicians within a hospital be-
fore a final decision is made, making it difficult to attribute
a treatment decision to a certain clinician. Third, informa-
tion provision and decisional support is often provided by
specialized (oncology) nurses. Typically they assist more
than one clinician, which could contaminate individual
clinicians’ data. Finally, regional variation in treatment
practices, which is expected to be influenced by DAs as
explained in previous sections, is generally reported at the
hospital level. This indicates that there are influences at
the hospital level driving practice variation that go be-
yond individual differences between clinicians within a
hospital. The reported variation in selected treatments
between hospitals is available for hospitals included in
our study, though no data is available on individual cli-
nician’s variability.
While carefully designed and reviewed by experts, some
content of the DA can remain the subject of discussion
among healthcare providers. As every urologist, radio-
therapist or nurse can be seen as an expert on prostate
cancer from their own perspective; all have their own pref-
erence in formulating and presenting options, facts and
risks involved to prostate cancer and its treatment alterna-
tives. The original DA is tested thoroughly and docu-
mented for the topics that should be addressed in the DA,
which we have taken over [23, 24]. All adjustments that
were made to adjust the DA to Dutch clinical setting are
based on the IPDAS criteria [25] for DA development. All
textual content is derived from Dutch and European treat-
ment guidelines.
A potential limitation of our DA is that a device with
internet connection is needed to use the DA, which
could affect our sample and consequently our findings.
Although we are aware that this could be a relevant
issue in many regions in the world, we do not expect
biased results in our trial. The World Bank has estimated
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in the world, with 94 % of the households (2013) having
internet access (www.worldbank.org). Even in older age
groups (65 to 75 years) regular internet access is at 80 %,
and this percentage is rapidly increasing (2013, Statistics
Netherlands). Internet is routinely referred to as part of
information provision in standard care. As most of our
questionnaires (in both groups) are sent via email, internet
access and the ability to use it is also required in both
groups, assuring group comparability on this matter.
Our trial has defined decisional conflict as primary
measure. As previously mentioned, the DCS is a widely
accepted and applied measure in DA evaluations. How-
ever, the DCS is also subject to some discussion in the lit-
erature about its usefulness as outcome measure in DA
evaluations [68]. This is mainly due to its limitation to
identify a good decision as a person’s underlying sensitivity
to uncertainty may not be fully represented in a high or
low decisional conflict score. For example, a high score on
the DCS could also represent the effort that one takes to
be involved in the decision-making process and absorbing
all available information and therefore becoming aware of
the difficulty of the decision. Although we are aware of
this potential limitation of the DCS, we believe decisional
conflict represents the best available affective-cognitive
outcome measure that captures the uncertainty involved
to prostate cancer treatment decision-making. Uncertainty
about disease progression, treatment success and side-
effect impact are key elements of the decision-making
process in prostate cancer care. Preliminary investigations
prior to the current study taught us that decisional con-
flict levels are substantial; we expect that our DA will be
able to reduce these levels and that this potential reduc-
tion is meaningful. For meaningful interpretation of our
effects we also have additional outcome measures avail-
able that can support our findings or can indicate bias if
present. Many of our secondary measures focus on the
decision-making process (knowledge, satisfaction with in-
formation provision, decision-making role) rather than
the outcome in terms of a ‘good’ or ‘bad’ decision, this en-
sures that our conclusions on the usefulness of the DA
will not solely depend on interpretation of the DCS.
On a broader level, this study will augment the current
paucity of information regarding the implementation of
DAs in (Dutch) routine clinical practice, its impact on
the treatment decision-making process and long-term
effects. This will help patients and clinicians to establish
optimal patient-treatment fit. As we hypothesized the ef-
fects could involve improved patient involvement and
knowledge resulting in higher decision and treatment
satisfaction and ultimately reduce regret and improve
quality of life.
Finally, the results of this project will contribute to the
increasing awareness of shared decision-making andimproving patient centered care in the treatment of
prostate cancer. This study can provide the scientific evi-
dence needed to include the use of a DA in the prostate
cancer treatment guidelines.
Trial status
This trial is currently recruiting patients. The start date
was August 2014. The initial patient inclusion is ex-
pected to take twelve months. Patients will be followed
for one year.
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